Incyte Co. (NASDAQ:INCY) Stock Position Lowered by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC decreased its holdings in shares of Incyte Co. (NASDAQ:INCY) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,197 shares of the biopharmaceutical company’s stock after selling 532 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Incyte were worth $1,326,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Global X Japan Co. Ltd. increased its stake in Incyte by 144.7% during the fourth quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 230 shares during the period. Brooklyn Investment Group acquired a new stake in Incyte during the 3rd quarter worth $30,000. R Squared Ltd bought a new position in shares of Incyte during the 4th quarter worth approximately $30,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Incyte in the third quarter valued at $33,000. Finally, Groupama Asset Managment lifted its holdings in Incyte by 11.4% during the 3rd quarter. Groupama Asset Managment now owns 59,597 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 6,105 shares during the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on INCY shares. UBS Group initiated coverage on Incyte in a report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 target price for the company. Royal Bank of Canada reduced their price objective on shares of Incyte from $70.00 to $68.00 and set a “sector perform” rating for the company in a research report on Tuesday, February 11th. JMP Securities reiterated a “market perform” rating on shares of Incyte in a report on Tuesday, February 11th. StockNews.com lowered Incyte from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Incyte in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Incyte presently has an average rating of “Hold” and a consensus target price of $75.25.

Incyte Trading Up 1.0 %

Shares of INCY stock opened at $70.79 on Friday. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $71.82 and a two-hundred day moving average price of $70.16. Incyte Co. has a 12-month low of $50.35 and a 12-month high of $83.95. The firm has a market cap of $13.70 billion, a P/E ratio of 262.19, a price-to-earnings-growth ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY) last released its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. Equities analysts anticipate that Incyte Co. will post 4.86 EPS for the current fiscal year.

Insider Activity at Incyte

In other Incyte news, insider Thomas Tray sold 650 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $70.64, for a total transaction of $45,916.00. Following the transaction, the insider now owns 23,962 shares in the company, valued at approximately $1,692,675.68. This represents a 2.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sheila A. Denton sold 599 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total value of $41,924.01. Following the completion of the sale, the executive vice president now directly owns 25,848 shares in the company, valued at approximately $1,809,101.52. This represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,320 shares of company stock worth $2,072,849 in the last 90 days. Company insiders own 17.60% of the company’s stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.